Reversal of hepatic fibrosis: more evidence and more challenges
10.3760/cma.j.cn501113-20220510-00255
- VernacularTitle:肝纤维化逆转：更多证据 更多挑战
- Author:
Jiayi ZHANG
1
;
Yameng SUN
;
Shuyan CHEN
;
Hong YOU
Author Information
1. 首都医科大学附属北京友谊医院肝病中心 国家消化系统疾病临床医学研究中心，北京 100050
- Keywords:
Liver fibrosis;
Regression;
Antifibrotic therapy;
New drugs
- From:
Chinese Journal of Hepatology
2022;30(6):569-571
- CountryChina
- Language:Chinese
-
Abstract:
Hepatic fibrosis is a response to various types of hepatic injury, which can lead to cirrhosis and its complications. In recent years, in patients with viral hepatitis, nonalcoholic steatohepatitis, alcoholic liver disease, autoimmune liver disease and others the fibrosis or even early cirrhosis can be regressed if the etiology are controlled. Liver biopsy is still the gold standard for assessing fibrosis reversal, but non-invasive methods such as transient elastography hold great promise due to the ease to use for dynamic monitoring. Mechanisms of hepatic fibrosis reversal include extracellular matrix degradation, hepatocyte regeneration, and vascular remodeling. Presently, novel agents targeting the steps of fibrosis are urgently need for achieving regression of liver fibrosis.
